Skip to content

Study · Not a test of the peptide alone · 2005

1 result

Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity.

Larsen LH, Echwald SM, Sørensen TI, Andersen T, Wulff BS, Pedersen O

The Journal of clinical endocrinology and metabolism14 Oct 2004Cited by 120 (Europe PMC)

PMID15486053 (opens in a new tab)DOI10.1210/jc.2004-0497 (opens in a new tab)PepBankPUB-15486053
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01LabNot a test of Melanotan II aloneIn vitro (cells)Activity measurement

    In vitro, the Ala219Val MC4R variant showed significantly impaired melanotan II induction of cAMP compared with the wild-type receptor.

    In plain wordsIn lab tests, an obesity-linked receptor variant responded less to melanotan II than the normal receptor.

    Peptide
    Melanotan II
    Outcome
    DecreaseMelanotan II induction of cAMP at the Ala219Val MC4R variant
    Study

    n: not reported in source

    Comparator
    Wild-type receptor
    Outcome group
    Receptor activity and mechanism · Metabolic and weight

    Source sentences

    Summary
    whereas the Ala219Val variant showed a significantly impaired melanotan II induction of cAMP, compared with the wild-type receptor

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.